Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 20/20 | 1.00 |
| ▸ | IDH2 | P48735 | 16/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Crelosidenib SCHEMBL29765374 | 1.00 | IDH1 (1.00) | IDH1IDH2 | |
| Crelosidenib SCHEMBL20270338 | 1.00 | IDH1 (1.00) | IDH1IDH2 | |
| Crelosidenib SCHEMBL20270341 | 1.00 | IDH1 (1.00) | IDH1IDH2 | |
| Crelosidenib SCHEMBL29427547 | 1.00 | IDH1 (1.00) | IDH1IDH2 | |
| Crelosidenib SCHEMBL20271764 | 1.00 | IDH1 (1.00) | IDH1IDH2 | |
| Crelosidenib SCHEMBL21799142 | 0.97 | IDH1 (0.94) | IDH1IDH2 | |
| SCHEMBL24170447 | 0.97 | IDH1 (0.94) | IDH1IDH2 | |
| SCHEMBL24170446 | 0.97 | IDH1 (0.94) | IDH1IDH2 | |
| SCHEMBL24170089 | 0.97 | IDH1 (0.94) | IDH1IDH2 | |
| SCHEMBL25227127 | 0.97 | IDH1 (0.94) | IDH1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240261294-A1 | METHOD FOR TREATING IDH INHIBITOR-RESISTANT SUBJECTS | ELI LILLY AND COMPANY | 2024-08-08 | — | — | US | claimed |
| EP-4125915-B1 | COMBINATION THERAPY WITH A MUTANT IDH INHIBITOR | LILLY CO ELI (US) | 2024-04-17 | — | — | EP | claimed |
| EP-4125917-B1 | COMBINATION THERAPY WITH A MUTANT IDH INHIBITOR AND A BCL-2 INHIBITOR | LILLY CO ELI (US) | 2024-04-17 | — | — | EP | claimed |
| EP-4125916-B1 | METHOD FOR TREATING IDH1 INHIBITOR-RESISTANT SUBJECTS | LILLY CO ELI (US) | 2024-04-17 | — | — | EP | claimed |
| EP-4337217-A1 | METHOD FOR TREATING IDH INHIBITOR-RESISTANT SUBJECTS | Eli Lilly and Company (US) | 2024-03-20 | — | — | EP | claimed |
| US-20230255973-A1 | COMBINATION THERAPY WITH A MUTANT IDH1 INHIBITOR, A DEOXYADENOSINE ANALOG, AND A PLATINUM AGENT | ELI LILLY AND COMPANY | 2023-08-17 | — | — | US | claimed |
| WO-2023141087-A1 | COMBINATION THERAPY WITH A MUTANT IDH INHIBITOR | ELI LILLY AND COMPANY (US) | 2023-07-27 | — | — | WO | claimed |
| US-20230146387-A1 | COMBINATION THERAPY WITH A MUTANT IDH INHIBITOR | ELI LILLY AND COMPANY | 2023-05-11 | — | — | US | claimed |
| US-20230135992-A1 | COMBINATION THERAPY WITH A MUTANT IDH INHIBITOR AND A BCL-2 INHIBITOR | ELI LILLY AND COMPANY | 2023-05-04 | — | — | US | claimed |
| EP-4125916-A1 | METHOD FOR TREATING IDH1 INHIBITOR-RESISTANT SUBJECTS | ELI LILLY AND COMPANY (US) | 2023-02-08 | — | — | EP | claimed |
| WO-2022261279-A1 | METHOD FOR TREATING IDH INHIBITOR-RESISTANT SUBJECTS | ELI LILLY AND COMPANY (US) | 2022-12-15 | — | — | WO | claimed |
| CN-115443137-A | Combination therapy using a mutant IDH inhibitor and a BCL-2 inhibitor | 伊莱利利公司 | 2022-12-06 | — | — | CN | claimed |
| CN-115335060-A | Combination therapy with mutant IDH inhibitors | 伊莱利利公司 | 2022-11-11 | — | — | CN | claimed |
| CN-115335059-A | Methods for treating IDH1 inhibitor resistant subjects | 伊莱利利公司 | 2022-11-11 | — | — | CN | claimed |
| CN-115109075-A | Mutant IDH1 and IDH2 inhibitors | 伊莱利利公司 | 2022-09-27 | — | — | CN | claimed |
| CN-110072867-B | 7-phenylethylamino-4H-pyrimido [4,5-D ] [1,3] oxazin-2-one compounds as inhibitors of mutant IDH1 and IDH2 | 伊莱利利公司 | 2022-07-08 | — | — | CN | claimed |
| US-11001596-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | ELI LILLY AND COMPANY (US) | 2021-05-11 | — | — | US | claimed |
| EP-3763717-A1 | PYRIDO[4,3-D][1,3]OXAZIN-2-ONE AND PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | ELI LILLY AND CO. (US) | 2021-01-13 | — | — | EP | claimed |
| EP-3555105-B1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | LILLY CO ELI (US) | 2020-10-28 | — | — | EP | claimed |
| US-20200079791-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | ELI LILLY AND COMPANY | 2020-03-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135992-A1 | COMBINATION THERAPY WITH A MUTANT IDH INHIBITOR AND A BCL-2 INHIBITOR | IDH2, IDH3B, IDH3A | IDH1 4/4885IDH2 1/4885 |
| US-20240261294-A1 | METHOD FOR TREATING IDH INHIBITOR-RESISTANT SUBJECTS | IDH3A, IDH2, IDH3B | IDH1 4/4885IDH2 2/4885 |
| US-20230255973-A1 | COMBINATION THERAPY WITH A MUTANT IDH1 INHIBITOR, A DEOXYADENOSINE ANALOG, AND A PLATINUM AGENT | IDH1, IDH3B, IDH3A | IDH1 1/4885IDH2 5/4885 |
| US-20200079791-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | IDH2, IDH1, IDH3B | IDH1 2/4885IDH2 1/4885 |
| US-11001596-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | IDH2, IDH1, IDH3B | IDH1 2/4885IDH2 1/4885 |
| US-20230146387-A1 | COMBINATION THERAPY WITH A MUTANT IDH INHIBITOR | IDH3B, IDH3A, FLT3 | IDH1 5/4885IDH2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.